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Original Article

Early High-Dose Vitamin D3 for Critically Ill,
Vitamin D–Deficient Patients
The National Heart, Lung, and Blood Institute PETAL Clinical Trials Network*

A BS T R AC T
BACKGROUND

Vitamin D deficiency is a common, potentially reversible contributor to morbidity
and mortality among critically ill patients. The potential benefits of vitamin D
supplementation in acute critical illness require further study.
METHODS

We conducted a randomized, double-blind, placebo-controlled, phase 3 trial of
early vitamin D3 supplementation in critically ill, vitamin D–deficient patients who
were at high risk for death. Randomization occurred within 12 hours after the
decision to admit the patient to an intensive care unit. Eligible patients received a
single enteral dose of 540,000 IU of vitamin D3 or matched placebo. The primary
end point was 90-day all-cause, all-location mortality.
RESULTS

A total of 1360 patients were found to be vitamin D–deficient during point-of-care
screening and underwent randomization. Of these patients, 1078 had baseline vitamin D deficiency (25-hydroxyvitamin D level, <20 ng per milliliter [50 nmol per
liter]) confirmed by subsequent testing and were included in the primary analysis
population. The mean day 3 level of 25-hydroxyvitamin D was 46.9±23.2 ng per
milliliter (117±58 nmol per liter) in the vitamin D group and 11.4±5.6 ng per milli
liter (28±14 nmol per liter) in the placebo group (difference, 35.5 ng per milliliter;
95% confidence interval [CI], 31.5 to 39.6). The 90-day mortality was 23.5% in the
vitamin D group (125 of 531 patients) and 20.6% in the placebo group (109 of 528
patients) (difference, 2.9 percentage points; 95% CI, −2.1 to 7.9; P = 0.26). There
were no clinically important differences between the groups with respect to secondary clinical, physiological, or safety end points. The severity of vitamin D deficiency at baseline did not affect the association between the treatment assignment and mortality.
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CONCLUSIONS

Early administration of high-dose enteral vitamin D3 did not provide an advantage
over placebo with respect to 90-day mortality or other, nonfatal outcomes among
critically ill, vitamin D–deficient patients. (Funded by the National Heart, Lung,
and Blood Institute; VIOLET ClinicalTrials.gov number, NCT03096314.)
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itamin D may improve outcomes in
critically ill patients. Preclinical data suggest that vitamin D is a potent immunomodulatory agent that is essential for lung development and function.1-7 Observational data and
initial clinical trial data indicate that vitamin D
deficiency is common among critically ill patients
and constitutes a potentially modifiable risk factor associated with longer lengths of stay in the
hospital and intensive care unit (ICU), lung and
other organ injury, prolonged mechanical ventilation, and death.8-14 However, vitamin D level is
considered a marker of coexisting conditions
and frailty, and residual confounding may drive
these associations.15
In a previous phase 2 trial (Correction of
Vitamin D Deficiency in Critically Ill Patients
[VITdAL-ICU], involving 475 patients), vitamin D
supplementation administered to vitamin D–deficient, critically ill patients was associated with
lower observed mortality than placebo at 28 days
(21.9% vs. 28.6%, P = 0.14) and at 6 months
(35.0% vs. 42.9%, P = 0.09), although the trial
was underpowered for analysis of the mortality
end point.16 Such findings, along with metaanalyses of previous trials in critical illness suggesting benefit of vitamin D treatment,17,18 support the need for a larger, phase 3 trial to evaluate
the effect of short-term vitamin D supplementation on mortality among critically ill patients.
Accordingly, the National Heart, Lung, and
Blood Institute (NHLBI) Prevention and Early
Treatment of Acute Lung Injury (PETAL) Network conducted the Vitamin D to Improve Outcomes by Leveraging Early Treatment (VIOLET)
trial. We hypothesized that early administration
of high-dose vitamin D3 (cholecalciferol) would
reduce 90-day all-cause, all-location mortality
among critically ill, vitamin D–deficient patients
who were at high risk for death.

Me thods
Trial Design and Oversight

We designed the present multicenter, doubleblind, placebo-controlled, phase 3 trial to have
many similarities to the previous phase 2 trial,16
including the vitamin D3 regimen (a single enteral
dose of 540,000 international units [IU]), the
threshold for vitamin D deficiency (25-hydroxy
vitamin D level, <20 ng per milliliter [50 nmol
per liter]), and a focus on critically ill patients.
2530
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Figure 1 (facing page). Screening, Enrollment,
and Follow-up.
Patients may have had more than one reason for being
excluded after the assessment of eligibility, and patients
who underwent randomization may have had more than
one reason for not receiving the assigned intervention.
ICU denotes intensive care unit, and LC-MS-MS liquid
chromatography–tandem mass spectrometry.

Key differences in the present trial included early
intervention (often before ICU admission), a focus
on patients with specific higher-risk conditions,
and a primary analysis based on measurement
of 25-hydroxyvitamin D by the criterion standard
of liquid chromatography–tandem mass spectrometry.19
The members of the writing committee vouch
for the accuracy and completeness of the data
and for the fidelity of the trial to the protocol
and statistical analysis plan, which are available
with the full text of this article at NEJM.org.
Oversight was provided by a central institutional
review board and data and safety monitoring
board of the sponsoring network, which were
appointed by the NHLBI. The trial was conducted
under an investigational new drug application
with the Food and Drug Administration (FDA).
The study network coordinating center managed
and analyzed the data. We obtained written informed consent from patients (when possible)
or from their authorized representatives. Sekisui
Diagnostics supplied the FastPack IP systems
and Bio-Tech Pharmacal developed and produced
the high-dose vitamin D3 and placebo used in the
trial, but neither company had any role in the trial
design or conduct, data analysis, or data interpretation.
Patients

We enrolled each patient within 12 hours after
the clinician’s decision to admit the patient to
the ICU from the emergency department, hospital ward, operating room, or outside facility. Eligible patients were adults and had one or more
acute risk factors for death or lung injury that
contributed directly to the need for ICU admission (pneumonia, sepsis, shock, mechanical ventilation for acute respiratory failure, aspiration,
smoke inhalation, pancreatitis, or lung contusion). The complete list of exclusion criteria is
shown in Figure 1, and in the Supplementary
Appendix, available at NEJM.org; the most com-
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15,924 Patients were assessed for eligibility

13,300 Were excluded
3942 Were unable to undergo randomization
within 12 hr after ICU admission
1967 Declined to participate or were
withdrawn by surrogate
1514 Were unable to take medication
by mouth or enteral tube
1422 Did not have surrogate who could
be located
828 Had >72 hr since hospital presentation
822 Decided to withhold or withdraw lifesustaining treatment
670 Had mechanical ventilation exclusions
599 Had known kidney stone in the past yr
or history of multiple (>1) previous
kidney stone episodes
571 Had baseline serum calcium >10.2 mg/dl
(2.55 mmol/liter) or ionized
calcium >5.2 mg/dl (1.30 mmol/liter)
524 Were expected to have <48-hr survival
1241 Had other reasons

2624 Provided consent

1264 Screened negative for vitamin D
deficiency

1360 Screened positive for vitamin D
deficiency

1360 Underwent randomization

2 Underwent randomization
but were not included in the
analysis
1 Received placebo but had not
provided adequate consent
1 Withdrew consent
690 Were assigned to vitamin D

668 Were assigned to placebo

14 Did not receive vitamin D
1 Was given placebo in error
1 Withdrew consent
2 Did not have trial drug
tube available
4 Could not take anything
by mouth
3 Did not have nasogastric
tube available
1 Was unavailable
3 Were not in stable
condition

17 Did not receive placebo
3 Were given vitamin D
in error
2 Withdrew consent
4 Could not take anything
by mouth
3 Did not have nasogastric
tube available
1 Was unavailable
6 Were not in stable
condition

538 Were confirmed by LC-MS-MS to have
vitamin D deficiency and were included
in the primary analysis population

540 Were confirmed by LC-MS-MS to have
vitamin D deficiency and were included
in the primary analysis population

7 Were lost to follow-up

12 Were lost to follow-up

531 Were included in the analysis of the
primary end point
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mon reasons for patients being excluded were an
inability to take an enteral drug, a history of
kidney stones, the presence of hypercalcemia at
baseline, and informed consent not being obtained in a timely manner. After written informed consent was obtained, eligible patients
underwent an FDA-approved test to screen for
vitamin D deficiency — either a test conducted
by the enrolling hospital clinical laboratory or a
point-of-care test (FastPack IP, Sekisui Diagnostics) performed by research staff. Eligible patients had a plasma 25-hydroxyvitamin D level of
less than 20 ng per milliliter as measured by
either test. This “screened-deficient” population,
which included all patients who underwent randomization, subsequently underwent confirmatory liquid chromatography–tandem mass spectrometry testing, which was completed at the
University of Washington reference laboratory
on batched plasma specimens that were collected at the same time as the initial screening test
(before randomization). Patients with a 25-hydroxy
vitamin D level of less than 20 ng per milliliter
as measured by liquid chromatography–tandem
mass spectrometry were considered to have confirmed vitamin D deficiency and made up the
primary analysis population. We also obtained
results for the screened-deficient population as
secondary analyses. Figure S1 in the Supplementary Appendix shows the flow of patients
through the trial.
Randomization

We used a central electronic system and permuted
blocks to randomly assign eligible patients in a
1:1 ratio, stratified according to site, to receive
either a single enteral (administered orally or
through a nasogastric or orogastric tube) dose of
540,000 IU of vitamin D3 or matched placebo, in
liquid form, administered within 2 hours after
randomization. We did not mandate other aspects of clinical care, because our intention was
to evaluate the intervention in the context of
usual practice. We recommended that treating
clinicians avoid vitamin D testing or additional
vitamin D supplementation in the 1 month after
administration of vitamin D or placebo.
End Points

The primary end point was 90-day all-cause, alllocation mortality in the primary analysis population (i.e., patients with vitamin D deficiency
2532
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confirmed by liquid chromatography–tandem
mass spectrometry). Secondary clinical end points
were hospital length of stay to day 90, health
care facility length of stay to day 90, proportions
of patients alive and at home (previous level of
care) at day 90, ventilator-free days to day 28,
time to death to day 90, and quality of life to day
90. Secondary physiological end points were the
severity of hypoxemia, acute respiratory distress
syndrome, acute kidney injury, and cardiovascular
failure to day 7, as well as 25-hydroxyvitamin D
levels at day 3 (measured in a subgroup of the
first 25% of patients per protocol). Safety end
points were total and ionized calcium levels to
day 14, incident kidney stones to day 90, and
fall-related fractures to day 90.
Statistical Analysis

We based the sample size on a comparison of
binomial proportions with an overall two-sided
alpha level of 0.05. Under assumptions that 90day mortality would be 20% in the placebo group
and 15% in the vitamin D group, that three interim data analyses would be conducted, and that
vitamin D deficiency would be confirmed by
liquid chromatography–tandem mass spectrometry in 80% of the patients undergoing randomization, we calculated that the trial would have
87% power if 3000 patients underwent randomization. The design allowed stopping for efficacy
on the basis of the Lan–DeMets alpha spending
function.20 The futility stopping rules incorporated the observed mortality and the proportion
of patients who underwent randomization who
had 25-hydroxyvitamin D levels of less than 20 ng
per milliliter as measured by liquid chromatography–tandem mass spectrometry to calculate
the predictive probability of vitamin D supplementation being shown to be significantly superior to placebo with 3000 patients. We adopted
a futility boundary of 10% posterior probability
of superiority at interim analyses.
For the primary analysis, we compared 90day mortality on the risk-difference scale using
a generalized linear model with a binomial distribution and identity link function. We used
quadratic smoothing splines with prespecified
knots at plasma 25-hydroxyvitamin D levels
(measured by liquid chromatography–tandem
mass spectrometry) of 5, 10, 15, 20, 25, and 30 ng
per milliliter and pointwise 95% bootstrap confidence intervals to estimate the relationship
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between the treatment effect and the baseline
25-hydroxyvitamin D level.21 We compared time
to death to day 90 using Kaplan–Meier curves.
We compared adverse events with the event as
the unit of analysis using weighted Poisson regression with serious events given a weight twice
that of the nonserious events.
We present other secondary end points with
observed differences and 95% Wald confidence
intervals. For the comparison of the highest creatinine levels and highest cardiovascular Sequential Organ Failure Assessment (SOFA) scores to
day 7, controlling for baseline values, we used
repeated-measures analysis of variance with a
treatment-by-time interaction and shared intercept at baseline. We analyzed hospital and health
care facility length of stay among patients who
survived to day 90 and changes in quality of life
as measured with the European Quality of Life–5
Dimensions 5-Level questionnaire (EQ-5D-5L)22
(score at day 90 minus score at baseline) using
survivor average causal effect methods, including
a model for predicting survival.23 In each treatment group, the estimated outcome in those
who would survive in both treatment groups is
a weighted average of the observed outcomes,
with weights proportional to the estimated probability of survival in the other treatment group.
The prespecified covariates were age, sex, race
or ethnic group, Charlson comorbidity index,
SOFA score, and baseline 25-hydroxyvitamin D
level measured by liquid chromatography–tandem
mass spectrometry. Beyond the survivor average
causal effect models, we conducted all analyses
using a complete case analysis approach, assuming that data were missing completely at random.
The main analyses used intention-to-treat
principles. We considered a two-sided P value of
less than 0.05 to indicate statistical significance
for the primary analysis. Other reported P values
(shown only for safety end points) and confidence intervals were not adjusted for multiple
comparisons and should not be used to infer
effects. We used SAS software, version 9.4 (SAS
Institute), for the analyses.

min D–deficient underwent randomization, and
1078 of these patients had vitamin D deficiency
confirmed by liquid chromatography–tandem
mass spectrometry and were included in the primary analysis population (Fig. 1). After the first
interim analysis, the data and safety monitoring
board recommended that the trial be stopped for
futility, primarily on the basis of a predictive
probability of less than 2% that vitamin D treatment would be found to be superior to placebo
with full trial enrollment.
Overall, 690 patients were assigned to the
vitamin D group and 668 patients were assigned
to the placebo group. In the primary analysis
population, 538 patients were in the vitamin D
group and 540 were in the placebo group. Baseline characteristics were similar in the two treatment groups in both the screened-deficient
population and the primary analysis population
(Table 1 and Table S1). The most common qualifying conditions were pneumonia, shock, and
sepsis. Randomization was performed at a mean
(±SD) of 6.7±3.5 hours after the clinician’s decision to admit the patient to the ICU (Table S2).
Plasma Vitamin D Levels

In the primary analysis population of 1078 patients, 532 (98.9%) of those who were randomly
assigned to the vitamin D group and 532 (98.5%)
of those who were randomly assigned to the
placebo group received the assigned treatment,
a mean of 1.2±1.1 hours after randomization
(Table S2). The mean baseline 25-hydroxyvitamin
D level as measured by liquid chromatography–
tandem mass spectrometry was 11.2±4.8 ng per
milliliter (28±12 nmol per liter) in the vitamin D
group and 11.0±4.7 ng per milliliter (27±12 nmol
per liter) in the placebo group (Table 1). In the
first 25% of patients who had day 3 plasma
specimens (per-protocol subgroup), the mean
day 3 level of 25-hydroxyvitamin D as measured by
liquid chromatography–tandem mass spectrometry was 46.9±23.2 ng per milliliter (117±58 nmol
per liter) in the vitamin D group and 11.4±5.6 ng
per milliliter (28±14 nmol per liter) in the placebo group (difference, 35.5 ng per milliliter;
95% confidence interval [CI], 31.5 to 39.6) (TaR e sult s
ble 2). In the vitamin D group, most patients
Patients
(74.5%) had reached the target 25-hydroxyvitaFrom April 2017 through July 2018 at 44 U.S. min D level of 30 to less than 120 ng per millihospitals, we obtained consent from 2624 pa- liter (75 to <300 nmol per liter) at day 3, with the
tients; 1360 patients who were screened as vita- levels in few patients (12.4%) remaining below
n engl j med 381;26
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Table 1. Baseline Characteristics of the Patients in the Primary Analysis Population.*
Characteristic

Demographic
Age — yr
Female sex — no. (%)
Race or ethnic group — no. (%)†
Non-Hispanic white
Black
Nonblack Hispanic
Other
Not available
Facility residence before hospitalization — no. (%)
EQ-5D-5L score‡
Clinical
Charlson comorbidity index§
Body-mass index¶
Acute risk factors for death — no. (%)‖
Pneumonia
Shock
Sepsis
Mechanical ventilation for acute respiratory failure
Aspiration
Lung contusion
Pancreatitis
Smoke inhalation
Medical ICU admission — no. (%)
Illness severity
Total SOFA score**
LIPS††
Mechanical ventilation — no. (%)
ARDS — no. (%)
Vasopressor use at baseline — no. (%)
Vitamin D–related
Vitamin D supplement use in past week — no. (%)
Multivitamin use in past week — no. (%)
Estimated average daily vitamin D dose — IU
25-hydroxyvitamin D level — ng/ml
Total calcium level — mg/dl
Ionized calcium level — mg/dl
Creatinine level — mg/dl
eGFR — ml/min/1.73 m2

Vitamin D (N = 538)
No. of Patients
Value
with Data

Placebo (N = 540)
No. of Patients
Value
with Data

56.5±15.9
229 (42.6)

538
538

54.6±16.7
238 (44.1)

540
540

280 (52.0)
130 (24.2)
33 (6.1)
15 (2.8)
80 (14.9)
33 (6.1)
0.7±0.3

538
538
538
538
538
538
507

287 (53.1)
122 (22.6)
31 (5.7)
12 (2.2)
88 (16.3)
35 (6.5)
0.7±0.3

540
540
540
540
540
540
504

4.0±2.9
29.8±10.1

522
524

3.5±2.9
31.0±11.4

521
529

204 (37.9)
192 (35.7)
185 (34.4)
119 (22.1)
27 (5.0)
15 (2.8)
17 (3.2)
1 (0.2)
447 (83.1)

538
538
538
538
538
538
538
538
538

181 (33.5)
197 (36.5)
174 (32.2)
121 (22.4)
35 (6.5)
18 (3.3)
19 (3.5)
2 (0.4)
462 (85.6)

540
540
540
540
540
540
540
540
540

5.6±3.6
5.3±2.9
173 (32.2)
44 (8.2)
169 (31.4)

538
538
538
538
538

5.4±3.7
5.3±3.1
184 (34.1)
44 (8.1)
177 (32.8)

540
540
540
540
540

31 (5.8)
38 (7.1)
3269±13,118
11.2±4.8
8.3±0.9
4.3±1.4
2.2±2.3
60±39.3

538
538
57

24 (4.4)
37 (6.9)
4252±15,094
11.0±4.7
8.3±0.9
4.3±0.9
2.0±2.0
60.9±36.9

540
540
54

528
210
535
535

526
212
539
539

*	Plus–minus values are means ±SD. The primary analysis population included all patients who underwent randomization and had vitamin D
deficiency confirmed by liquid chromatography–tandem mass spectrometry. Percentages may not total 100 because of rounding. To con‑
vert the values for 25-hydroxyvitamin D to nanomoles per liter, multiply by 2.496. To convert the values for calcium to millimoles per liter,
multiply by 0.250. To convert the values for creatinine to micromoles per liter, multiply by 88.4. ARDS denotes acute respiratory distress
syndrome, and eGFR estimated glomerular filtration rate.
†	Race and ethnic group were reported by the patient or the patient’s surrogate.
‡	Scores on the EuroQol–5 Dimensions 5-Level quality-of-life assessment (EQ-5D-5L) range from −0.11 to 1.00, with higher scores indicating
better health.
§	Charlson comorbidity index scores range from 0 to 37, with higher scores indicating more coexisting conditions.
¶	Body-mass index is the weight in kilograms divided by the square of the height in meters.
‖	Patients may have had more than one risk factor.
**	The total Sequential Organ Failure Assessment (SOFA) score ranges from 0 to 24, with higher scores indicating more severe organ failure.
††	The Lung Injury Prediction Score (LIPS) ranges from 0 to 36, with higher scores indicating a higher risk of lung injury.
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20 ng per milliliter (Table 2). In the placebo
group, 94.0% of patients had 25-hydroxyvitamin D
levels that remained below 20 ng per milliliter at
day 3. These results were similar in the screeneddeficient population (Tables S1 and S3).
Primary End Point

In the primary analysis population, 90-day allcause, all-location mortality was 23.5% in the
vitamin D group (125 of 531 patients) and 20.6%
in the placebo group (109 of 528 patients) (difference, 2.9 percentage points; 95% CI, −2.1 to
7.9; P = 0.26) (Table 2 and Fig. 2). In the screeneddeficient population, 90-day all-cause, all-location
mortality was 23.3% in the vitamin D group
(159 of 681 patients) and 20.9% in the placebo
group (137 of 656 patients) (difference, 2.5 percentage points; 95% CI, −2.0 to 6.9; P = 0.28)
(Table S3 and Fig. S2). On the basis of the range
of baseline 25-hydroxyvitamin D levels and prespecified thresholds for this measurement, there
was no apparent interaction between treatment
group and the baseline 25-hydroxyvitamin D
level (Fig. 3 and Figs. S2 and S3 and Table S4).
The observed mortality was higher in the vitamin D group than in the placebo group for
several subgroups: patients with sepsis or infection in the primary analysis population and prehospital facility residence, pneumonia, infection,
and prerandomization acute respiratory distress
syndrome in the screened-deficient population.
Secondary End Points

In the primary analysis population, mortality to
day 28, hospital mortality to day 90, hospital
and health care facility length of stay, ventilatorfree days, and change in EQ-5D-5L score did not
differ significantly between the groups (Table 2).
The postrandomization incidence of acute respiratory distress syndrome did not differ significantly between the two treatment groups (4.9%
in the vitamin D group and 4.1% in the placebo
group; difference, 0.7 percentage points; 95%
CI, −2.1 to 3.6). Other physiological end points,
including respiratory, kidney, and cardiovascular
failure, were also similar in the two groups.
Results for secondary end points were similar in
the screened-deficient population.
Safety and Adverse Events

Safety and adverse events are summarized in
Table 2 and Tables S5 through S7. Although
there were 296 total deaths reported in the trial,
n engl j med 381;26

none were adjudicated as being causally related to
vitamin D or placebo. Prespecified vitamin D–
related adverse events (hypercalcemia, kidney
stones, and fall-related fractures) were similar in
the two groups. There was a small increase in
the highest total calcium level to day 14 in the
vitamin D group. Similarly, there were small
increases in total and ionized calcium levels according to trial day in the vitamin D group in the
primary analysis population and the screeneddeficient population. Reported serious and nonserious adverse events were uncommon and
similar in the vitamin D and placebo groups
across the populations.

Discussion
A single 540,000 IU enteral dose of vitamin D3
administered early during critical illness rapidly
corrected vitamin D deficiency but did not provide an advantage over placebo with respect to
mortality or other clinically important end points.
The very low likelihood of finding a benefit justified stopping the trial for futility before the
pretrial sampling target of up to 3000 patients
had been reached. We enrolled the intended
population in a blinded fashion, with 90-day
mortality similar to the predefined estimated rate,
and a robust vitamin D response was achieved,
with few adverse events. No predefined subgroups appeared to benefit from the vitamin D
supplementation, including those with more severe vitamin D deficiency and those with specific acute risk factors for death. Furthermore,
the higher observed mortality in the vitamin D
group among patients with infectious causes of
illness and patients with prerandomization acute
respiratory distress syndrome was unexpected
and contrary to the reported immunomodulatory
effects of vitamin D. This observation may reflect differences between the use of vitamin D
for prevention in previous studies24 and the use
of vitamin D as treatment during acute illness in
the present trial, but it also may be the result of
chance.
There are several important differences between the current phase 3 trial and the previous,
phase 2 trial (VITdAL-ICU).16,25 First, we enrolled
patients early in their critical illness, often before arrival in the ICU, to correct vitamin D deficiency before established critical illness. The
phase 2 trial enrolled patients a mean of 3 days
after admission to the ICU. Second, the current
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6 (30.0)
9 (45.0)

Moderate

20 (4.9)

179.8±102.6

Mild

ARDS severity to day 7 — no. (%)

New ARDS to day 7 — no. (%)

Mean ±SD lowest Pao2:Fio2 to day 7

New, postrandomization mechanical ventilation — no. (%)

39 (10.7)

0.0±0.0

Mean ±SE†

Secondary physiological end points

0.0±0.2

Mean ±SD

Change in EQ-5D-5L from baseline to day 90

20

20

411

122

365

340

340

523

402

402

12 (70.6)

4 (23.5)

17 (4.1)

185.8±110.4

29 (8.2)

0.0±0.0

0.0±0.2

22.1±10.5

7.5±0.7

8.1±20.4

89 (21.2)

9.9±0.4

10.4±11.0

17

17

412

136

354

346

346

534

416

416

419

418

418

526

539

528

528

No. of Patients
with Data

−25.6 (−56.3 to 5.1)

6.5 (−22.0 to 34.9)

0.7 (−2.1 to 3.6)

−5.9 (−32.2 to 20.3)

2.5 (−1.8 to 6.8)

0.0 (0.0 to 0.1)

0.0 (0.0 to 0.1)

−0.8 (−2.1 to 0.5)

−1.9 (−3.8 to −0.1)

−2.2 (−4.8 to 0.4)

−3.8 (−9.1 to 1.6)

−0.9 (−1.9 to 0.1)

−1.4 (−2.7 to 0.0)

0.3 (−5.4 to 6.0)

3.7 (−0.5 to 8.0)

4.3 (−0.1 to 8.6)

0.26

P Value or Difference
(95% CI)

of

21.3±11.3

5.5±0.7

Mean ±SE†

406

406

406

345 (65.6)

72 (13.4)

69 (13.1)

109 (20.6)

Value

Placebo
(N = 540)

n e w e ng l a n d j o u r na l

Mean ±SD ventilator-free days to day 28

6.0±17.5

Mean ±SD

Health care facility length of stay — days

71 (17.5)

Mean ±SE†

Discharged to other health care facility — no. (%)

9.1±9.2

Mean ±SD

Hospital length of stay to day 90 — days

538
528

92 (17.1)
348 (65.9)

Death in the hospital to day 90 — no. (%)

Alive and at home under previous level of care at day 90 — no. (%)

531

No. of Patients
with Data

531

125 (23.5)

Value

Vitamin D
(N = 538)

92 (17.3)

Death from any cause in any location to day 28 — no. (%)

Secondary clinical end points

Death from any cause in any location to day 90 — no. (%)

Primary end point

End Point

Table 2. End Points in the Primary Analysis Population.*
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1.4±0.1
46.9±23.2

Mean ±SE highest cardiovascular SOFA score to day 7‡

Mean ±SD 25-hydroxyvitamin D level at day 3 — ng/ml
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4.7±0.8

Mean ±SD highest ionized calcium level to day 14 — mg/dl

4 (0.8)

Fall-related fractures to day 90 — no. (%)

518

507

507

507

153

507

513

141

145

145

145

145

145

523

357

2 (0.4)

27 (5.3)

3 (0.6)

4.6±0.8

8.8±0.7

11 (2.1)

17

298±2219

0

0

8 (6.0)

125 (94.0)

11.4±5.6

1.3±0.1

42 (11.7)

2.1±0.1

18 (3.6)

69 (13.9)

52 (10.5)

77 (15.6)

297 (60.0)

1 (5.9)

Value

Placebo
(N = 540)

507

507

507

177

513

523

125

133

133

133

133

133

534

360

528

500

495

495

495

495

17

No. of Patients
with Data

0.69

0.24

0.25

0.67

0.004

0.51

0.47

−82 (−543 to 378)

0.7 (−0.7 to 2.0)

74.5 (67.4 to 81.6)

6.4 (−0.3 to 13.1)

−81.6 (−88.3 to −74.9)

35.5 (31.5 to 39.6)

−0.1 (−0.3 to 0.0)

0.4 (−4.4 to 5.1)

0.0 (−0.2 to 0.1)

0.5 (−1.9 to 2.9)

2.8 (−1.7 to 7.3)

−0.6 (−4.4 to 3.2)

−1.1 (−5.6 to 3.4)

−1.1 (−7.3 to 5.0)

19.1 (−2.9 to 41.1)

P Value or Difference
(95% CI)

*	To convert the values for calcium to millimoles per liter, multiply by 0.250. Pao2:Fio2 denotes the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen.
†	Values were calculated from a survivor average causal effect model.
‡	Cardiovascular SOFA scores range from 0 to 4, with higher scores indicating more severe organ failure. Values were controlled for the baseline value with the use of repeated-measures
analysis of variance with a treatment-by-time interaction and shared intercept at baseline.

36 (7.1)

Falls to day 90 — no. (%)

0

8.9±0.8

Mean ±SD highest total calcium level to day 14 — mg/dl

Kidney stones to day 90 — no. (%)

14 (2.7)

13

216±1574

Hypercalcemia to day 14 — no. (%)

Serious adverse events — no.

Secondary safety end points

Mean ±SD interleukin-6 level at day 3 — pg/ml

1 (0.7)

108 (74.5)

30 to <120 ng/ml

≥120 ng/ml

18 (12.4)
18 (12.4)

<20 ng/ml

20 to <30 ng/ml

25-Hydroxyvitamin D level category at day 3 — no. (%)

2.2±0.1
43 (12.0)

Mean ±SE highest creatinine level to day 7 — mg/dl‡

New vasopressor use to day 7 — no. (%)

489

81 (16.7)
20 (4.1)

New renal-replacement therapy to day 7 — no. (%)

Severe

484
484

70 (14.5)
48 (9.9)

Mild

Moderate

20

No. of Patients
with Data

484

5 (25.0)

Value

Vitamin D
(N = 538)

285 (58.9)

None

Worst severity of acute kidney injury to day 7 — no. (%)

Severe

End Point
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Figure 2. Survival to Day 90 in the Primary Analysis Population.
This figure is descriptive and not intended for inference of effects.

50

Placebo
Vitamin D

Mortality (%)

40
30
20
10
0

0

5

10

15

20

25

30

35

Baseline 25-Hydroxyvitamin D (ng/ml)

Figure 3. Mortality to Day 90 According to Baseline 25-Hydroxyvitamin D
Level among All Patients Who Underwent Randomization.
I bars represent 95% confidence intervals. Plasma 25-hydroxyvitamin D
concentrations were measured by liquid chromatography–tandem mass
spectrometry. Estimates were obtained from the quadratic smoothing spline
in each treatment group with prespecified knots at plasma 25-hydroxyvita‑
min D levels of 5, 10, 15, 20, 25, and 30 ng per milliliter and pointwise 95%
bootstrap confidence intervals. To convert the values for 25-hydroxyvitamin D
to nanomoles per liter, multiply by 2.496.

trial primarily enrolled typical medical patients
in the ICU (e.g., patients with pneumonia, sepsis, shock, or respiratory failure), whereas more
than three quarters of the patients in the phase 2
trial were surgical or neurologic patients in the
ICU. Third, we did not provide additional vita-
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min D supplementation after the initial loading
dose, on the basis of the expected 2-to-3-week
half-life of 25-hydroxyvitamin D,11,15,16 which we
believed was adequate. Fourth, to maximize the
inclusion of patients who were most likely to
benefit from vitamin D supplementation, our
primary analysis was based on liquid chromatography–tandem mass spectrometry testing, the
criterion standard for 25-hydroxyvitamin D measurement. However, the results were not material
ly different in the screened-deficient population.
Fifth, the population in the present trial had
racial and ethnic diversity representative of the
U.S. population; the phase 2 trial was conducted
in Austria, and more than 99% of the patient
population was white. Given known differences
in vitamin D metabolism and response genes
according to race and ethnic group,26-28 such differences may affect the results.
The results of the present trial do not support
early testing for or treatment of vitamin D deficiency in critically ill patients. Ongoing studies
will evaluate the effect of vitamin D supplementation in patients with severe vitamin D deficiency (ClinicalTrials.gov number, NCT03188796),
other subgroups of patients that may be more
likely to benefit (National Institutes of Health
project number R01HL144566), and long-term
outcomes (NCT03733418).
The strengths of our trial included a large,
diverse, and representative population of patients
with critical illness who were efficiently enrolled
early during their critical illness. Our trial also
achieved strong separation between the groups,
with rapid correction of vitamin D deficiency.
The trial also had certain limitations. One was
the exclusion of patients later in the course of
critical illness, which may have biased the trial
population toward patients with less severe illness because of an inability to obtain timely
informed consent from patients who had more
severe illness. We did not follow the outcomes
among patients who did not undergo randomization because they were found not to be vitamin D–deficient during screening. Finally, we
did not provide additional vitamin D supplementation after the loading dose, since our intent
was early correction of vitamin D deficiency.
In this phase 3 trial, early administration of
high-dose enteral vitamin D3 did not provide an
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advantage over placebo with respect to 90-day
mortality or other measures of nonfatal outcomes among critically ill patients with vitamin
D deficiency.
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